Meeting
2018 Gastrointestinal Cancers Symposium
Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.
Authors
Suayib Yalcin
Hacettepe University, Ankara, Turkey
Suayib Yalcin , Faysal Dane , Berna Oksuzoglu , Nuriye Yildirim , Abdurrahman Isikdogan , Metin Ozkan , Guzin Demirag , Hasan Senol Coskun , Bulent Karabulut , Turkkan Evrensel , Mehmet Ali Ustaoglu , Feyyaz Ozdemir , Hande Turna , Tugba Yavuzsen , Faruk Aykan , Alper Sevinc , Hakan Akbulut , Deniz Yuce , Mutlu Hayran , Saadettin Kilickap
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
EudraCT: 2013-004180-32
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 346)
DOI
10.1200/JCO.2018.36.4_suppl.346
Abstract #
346
Poster Bd #
G7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Dong-Sheng Zhang
Poster
2023 ASCO Annual Meeting
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.
First Author: Vincent Chung
Poster
2022 ASCO Annual Meeting
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186—Trials in progress.
First Author: Efrat Dotan
Poster
2020 ASCO Virtual Scientific Program
Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: BIBABRAX study.
First Author: Jaime Feliu Batlle